Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCP1904-1
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HCP1904-1 is a small molecule drug developed by Hanmi Pharmaceutical Co., Ltd. It is being investigated primarily for the treatment of essential hypertension, a cardiovascular disease characterized by high blood pressure. The drug's mechanism of action and detailed pharmacology have not been fully disclosed publicly, but it is under clinical evaluation for safety, tolerability, and efficacy in patients with essential hypertension inadequately controlled on other therapies. Clinical trials include randomized, double-blinded, active-controlled Phase III studies assessing its efficacy and safety profile in hypertensive patients.
- Other names
- HCP1904-1HCP-1904-1HCP 1904-1
Beyond the preview
Go deeper on HCP1904-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCP1904-1.